Is Atreca, Inc. (BCEL) a Buy, Sell, or Hold?
NASDAQ : BCEL
Atreca, Inc.
$0.09 USD
$0.0 (-1.32%)
- Volume
- 122.12K
- Average Volume
- 169.76K
- Market Capitalization
- $3.57M
- P/E Ratio
- -0.04
- Dividend Yield
- 0.00%
- Price Target
- $4.00
- Year High
- $1.20
- Year Low
- $0.05
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.79
Company Overview
NASDAQ
John A. Orwin
Biotechnology
Healthcare
BCEL
90
US
USD
Liquidity Metrics
0.81
4.79
4.79
1.89
0.00
Sales & Valuation
$770K
4.63
0.04
-0.04
-2.11
Profitability
-$2.35
-$97.16M
-12617.79%
-12617.79%
-83.28%
-62.67%
P/E Metrics
-0.04
0.00
0.00
Analyst Price Target & Rating
$4.00
$4.00
$4.00
0/5
8 Analysts
-97.75%
Financial Health Scores
-37.57
3/9
$9.11M
$26.34M
$15.58M
-$78.11M
Key Metrics (TTM)
$36.62M
47.56
-0.40
4.79
-83.28%
-68.54%
-2797.13%
-2286.66%
1799 days
Company Executives
| Name | Title |
|---|---|
| John A. Orwin | President, Chief Executive Officer, Director & Principal Financial Officer |
| Rick Ruiz | Principal Accounting Officer |
| Tito A. Serafini | Founder & Director |
| Courtney J. Phillips | General Counsel & Corporate Secretary |
| Roger Richard Ruiz | Vice President of Finance |
Poll Results
No votes yet today — be the first to share your view!
About Atreca, Inc. (NASDAQ:BCEL) Stock
Atreca, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing antibody-based immunotherapies for various solid tumor indications. Its lead investigational therapeutic, ATRC-101, is a monoclonal antibody distinguished by its novel mechanism of action and a unique target, both identified through the company's proprietary discovery platform. In in vitro studies, ATRC-101 has demonstrated reactivity with a significant proportion of human ovarian, non-small cell lung, colorectal, and breast cancer samples sourced from diverse patient populations. The pipeline also includes APN-122597, a receptor tyrosine kinase engineered to specifically target tumor tissues, and ATRC-501/MAM01, an agent aimed at the circumsporozoite protein of Plasmodium falciparum for malaria ... treatment. Beyond its internal programs, Atreca maintains strategic alliances, including a collaboration and licensing agreement with Xencor, Inc. for the research, development, and commercialization of innovative CD3 bispecific antibodies in oncology. Additionally, it holds a licensing agreement with the Bill & Melinda Gates Medical Research Institute for the advancement and commercialization of MAM01/ATRC-501, specifically for malaria prevention. Founded in 2010, Atreca, Inc. is headquartered in San Carlos, California.
Frequently Asked Questions
-
What is the current Atreca, Inc. (BCEL) stock price?
-
Atreca, Inc.(NASDAQ:BCEL) stock price is $0.09 in the last trading session. During the trading session, BCEL stock reached the peak price of $1.2 while $0.052 was the lowest point it dropped to. The percentage change in BCEL stock occurred in the recent session was --1.32% while the dollar amount for the price change in BCEL stock was -$0.0.
-
BCEL's industry and sector of operation?
-
The NASDAQ listed BCEL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BCEL?
-
John A. Orwin | President, Chief Executive Officer, Director & Principal Financial Officer
Rick Ruiz | Principal Accounting Officer
Tito A. Serafini | Founder & Director
Courtney J. Phillips | General Counsel & Corporate Secretary
Roger Richard Ruiz | Vice President of Finance -
How many employees does BCEL have?
-
Number of BCEL employees currently stands at 90. BCEL operates from 835 Industrial Road, South San Francisco, CA 94070, US.
-
Link for BCEL official website?
-
Official Website of BCEL is: https://www.atreca.com
-
How do I contact BCEL?
-
BCEL could be contacted at phone #650 595 2595 and can also be accessed through its website. BCEL operates from 835 Industrial Road, South San Francisco, CA 94070, US.
-
How many shares of BCEL are traded daily?
-
The average number of BCEL shares traded daily for last 3 months was 169.76K.
-
What is the market cap of BCEL currently?
-
The market value of BCEL currently stands at $3.57M with its latest stock price at $0.09